|
96 |
기타암 |
PD-L1-Expression in primary and recurrent vulvar squamous cell cancer
|
2025-03-20 |
31 |
|
95 |
기타암 |
Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study
|
2025-03-20 |
8 |
|
94 |
기타암 |
What happens after menopause? (WHAM): A prospective controlled study of cognition 24 months after premenopausal risk-reducing salpingo-oophorectomy
|
2025-03-20 |
6 |
|
93 |
난소암 |
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results
|
2025-03-20 |
22 |
|
92 |
난소암 |
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
|
2025-03-20 |
6 |
|
91 |
난소암 |
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
|
2025-03-20 |
2 |
|
90 |
난소암 |
Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18)
|
2025-03-20 |
8 |
|
89 |
난소암 |
Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial
|
2025-03-20 |
4 |
|
88 |
자궁경부암 |
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
|
2025-03-20 |
16 |
|
87 |
자궁경부암 |
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study☆
|
2025-03-20 |
13 |
